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 The emergence and spread of multi-drug resistant 
tuberculosis (MDR-TB) is threatening to destabilize 
global tuberculosis control. The prevalence of MDR-
TB is increasing throughout the world both among 
new tuberculosis cases as well as among previously-
treated ones1. Although previous treatment for TB is 
the strongest risk factor for development of MDR-
TB2-4, treatment-naïve patients are also at risk due 
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Background & objectives: The prevalence of multidrug-resistant tuberculosis (MDR-TB) is increasing 
throughout the world. Although previous treatment for TB is the most important risk factor for 
development of MDR-TB, treatment-naïve patients are also at risk due to either spontaneous mutations 
or transmission of drug-resistant strains. We sought to ascertain the prevalence of MDR-TB among new 
cases of sputum-positive pulmonary TB.
Methods: This was a prospective, observational study involving newly diagnosed cases of sputum-positive 
pulmonary tuberculosis diagnosed between 2008 and 2009 carried out in New Delhi, India. All sputum-
positive TB cases were subjected to mycobacterial culture and first-line drug-susceptibility testing (DST). 
MDR-TB was defined as TB caused by bacilli showing resistance to at least isoniazid and rifampicin.
Results: A total of 218 cases of sputum-positive pulmonary tuberculosis were enrolled between 2008 and 
2009. Of these, 41 cases had negative mycobacterial cultures and DST was carried out in 177 cases. The 
mean age of the patients was 27.8 ± 10.2 yr; 59 patients (27%) were female. All patients tested negative 
for HIV infection. Out of 177 cases, two cases of MDR-TB were detected. Thus, the prevalence of MDR-
TB among newly diagnosed pulmonary tuberculosis patients was 1.1 per cent.
Interpretation & conclusions: MDR-TB prevalence is low among new cases of sputum-positive pulmonary 
TB treated at primary care level in Delhi. Nation-wide and State-wide representative data on prevalence 
of MDR-TB are lacking. Efforts should be directed towards continued surveillance for MDR-TB among 
newly diagnosed TB cases.
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to either spontaneous mutations or transmission 
of resistant strains5,6. The risk of transmission of 
resistant strains from close contacts is increasing 
day-by-day because of the growing burden of MDR-
TB patients1. Therefore, in the present scenario, 
there is high likelihood that what initially seems to 
be drug-sensitive TB in a treatment-naïve patient 
might in fact be MDR-TB from the outset. Therefore, 
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we sought to determine the prevalence of MDR-TB 
among new cases of sputum-positive pulmonary 
TB. 
Material & Methods
 This was a prospective, observational study 
involving newly diagnosed cases of sputum-positive 
pulmonary tuberculosis. These are preliminary results 
from an ongoing double-blind, placebo-controlled 
trial. The cases were recruited through a dedicated 
chest clinic functioning at primary care level at 
Sanjay Gandhi Memorial Hospital in Mongolpuri, 
New Delhi. All suspected cases of TB attending the 
clinic were subjected to sputum smear examination 
and mycobacterial culture and drug-susceptibility 
testing (DST) at the New Delhi Tuberculosis (NDTB) 
Centre laboratory, New Delhi. The NDTB centre was 
accredited as the intermediate reference laboratory 
(IRL) during the study period. Sputum-positive 
pulmonary TB was defined as TB in a patient with 
at least 2 initial sputum smear examinations positive 
for acid-fast bacilli (AFB) or one sputum smear 
examination positive for AFB and radiographic 
abnormalities consistent with active pulmonary TB 
or one sputum smear specimen positive for AFB and 
culture positive for Mycobacterium tuberculosis7. 
New case was defined as a TB patient who has never 
had treatment for tuberculosis or has taken anti-
tuberculosis drugs for less than one month7. Cultures 
were done on Lowenstein-Jensen (L-J) slopes by 
modified Petroff’s method8. All the isolates were 
identified as M. tuberculosis by their slow growth 
rate, colony morphology, inability to grow on L-J 
media containing p-nitrobenzoic acid (PNB), niacin 
test and catalase test. DST was carried out by the 
economic variant of 1 per cent proportion method for 
all drugs except pyrazinamide which was tested by 
the resistance-ratio method. The tested drugs and their 
critical concentrations (in µg/ml) were as follows: 
isoniazid (H)- 0.2, rifampicin (R)- 40, pyrazinamide 
(Z) - 100, ethambutol (E) - 2 and streptomycin (S) - 4. 
MDR-TB was defined as TB caused by bacilli showing 
resistance to at least isoniazid and rifampicin. Human 
immunodeficiency virus (HIV) testing was carried 
out routinely in all patients and HIV positive patients 
were excluded from the study. Written informed 
consent was obtained from all patients. The Ethical 
Committee of AIIMS hospital, New Delhi approved 
the study protocol.
Results 
 We prospectively enrolled 218 cases of newly 
diagnosed sputum-positive pulmonary tuberculosis 
between February 2008 and December 2009. Of the 
218 cases, 41 patients had negative mycobacterial 
cultures and hence DST was carried out in 177 cases. 
The mean age of the patients was 27.8 ± 10.2 yr; 59 
(27%) were female. The mean body mass index (BMI) 
was 17.33 ± 1.99 kg/m2. Out of 177 cases, two cases 
of MDR-TB were detected. Both were male, HIV 
negative, aged 20 and 25 yr with BMI 17.1 and 19.7 
kg/m2, and resistance pattern was H, R, S and H, R, 
E, S, respectively. Thus, the prevalence of MDR-TB 
among new sputum positive pulmonary TB patients 
was 1.1 per cent. The resistance rates (%) observed to 
various first-line drugs were isoniazid 6.2, rifampicin 
1.1, pyrazinamide 0, ethambutol 3.4, and streptomycin 
2.3. The rates of mono- and poly-drug resistance rates 
are shown in Table I. 
Discussion 
 We found a low prevalence of MDR-TB among 
new cases of pulmonary TB in Delhi. The reported 
prevalence of MDR-TB among new TB cases has 
varied from 0.14 to 5.3 per cent in previous studies 
from different parts of India8-19 and our findings are 
in consonance with such observations (Table II). But 
there are a few studies which have reported a high 
prevalence of MDR-TB among new TB cases20,21. Bias 
in patient selection and differences in methodology 
may account for such high prevalence of MDR-TB 
noted in these studies. 
Table I. Mono- and poly-drug resistance rates in patients
Drug Resistance  
rate (%)
Isoniazid 1.7
Rifampicin 0
Pyrazinamide 0
Ethambutol 0
Streptomycin 0
Isoniazid + Ethambutol 2.3
Isoniazid + Streptomycin 0.6
Isoniazid + Rifampicin + Streptomycin 0.6
Isoniazid + Ethambutol + Streptomycin 0.6
Isoniazid + Rifampicin Ethambutol + 
Streptomycin
0.6
Note: The drug combinations not mentioned in this Table had 0% 
resistance.
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 Our findings carry some important implications. 
Firstly, the prevalence of MDR-TB has not risen over the 
years, which reflects the success of DOTS in effective 
treatment of drug-susceptible TB and preventing the 
emergence of MDR-TB. Secondly, since MDR-TB is 
rare among new TB cases, all new cases of pulmonary 
tuberculosis can be treated with empirical category 
I regimen without the risk of treatment failures or 
aggravation of drug-resistance.
 The major limitation of the present study is the small 
sample size and therefore, it is not representative of the 
population at large. In fact, this limitation was observed 
in most previous studies on MDR-TB. Nation-wide 
and State-wide representative data on the prevalence 
of MDR-TB are an urgent need of the hour to design 
effective empirical regimens, to monitor functioning 
and progress of the national TB control programme 
and for continued surveillance of MDR-TB among 
category I TB patients. In conclusion, our findings are 
quite reassuring in that MDR-TB prevalence has not 
risen over the years and still continues to be low among 
new cases of pulmonary TB.
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